The Zhitong Finance App learned that CICC released a research report stating that it maintained the “outperform the industry” rating of Jin Xin Breeding (01951), lowered the adjusted net profit forecast for 2022-23 by 55%/33% to 269/495 million yuan, and introduced the 2024 adjusted net profit forecast of 739 million yuan. Considering the restoration of the sector's valuation center and the long-term development space of the industry and companies, the target price is HK$8.8, which has 20% room for an increase from the current stock price. Recently, the National Health Insurance Administration clearly stated in its response letter to CPPCC members' proposals that it would gradually include appropriate assisted reproductive technology projects in the scope of health insurance fund payments.

The report mentioned that recently, in its response letter to CPPCC members' relevant proposals, the National Health Insurance Administration once again made it clear that it wants to promote the inclusion of assisted reproductive technology in health insurance to reduce the medical burden of infertility patients. Influenced by factors such as patients' perceptions, availability of high-quality technology, and ability to pay, the penetration rate of assisted reproductive technology in China is still at a low level. The bank believes that in the future, as the country promotes the inclusion of assisted reproductive technology in medical insurance and reduces the pressure on patients to pay, it is expected that the penetration rate will continue to increase; at the same time, with a series of fertility support measures and the decline in IVF technology, the overall scale of the industry is expected to maintain steady long-term growth.